Journal of Neuro-Oncology最新文献

{"title":"Prognostic value of temporal muscle thickness in pediatric medulloblastoma patients aged 3-12 years.","authors":"Xu An, Junhua Wang, Jingzhe Yuan, Xuan Zhou, Xiaozhu Liu, Xiaoyan Sun, Jian Gong, Qingnan Wu, Yunwei Ou","doi":"10.1007/s11060-025-05229-0","DOIUrl":"10.1007/s11060-025-05229-0","url":null,"abstract":"<p><strong>Purpose: </strong>This retrospective, multicenter cohort study aimed to investigate the prognostic significance of temporal muscle thickness (TMT) in medulloblastoma (MB) patients.</p><p><strong>Methods: </strong>Preoperative cranial MRI was used to measure TMT. Patients were divided into training and test cohorts. An optimal TMT cutoff for progression-free survival (PFS) and overall survival (OS) was established.</p><p><strong>Results: </strong>Among the 303 enrolled MB patients, TMT was found to be associated with prognosis in the 230 patients aged 3-12 years. TMT demonstrated positive correlations with age and body mass index, while inverse associations were observed with the presence of hydrocephalus and metastasis. A TMT cutoff value of 6.115 mm was established in the training cohort, which served as a significant threshold for both PFS and OS. The 5-year PFS rates were (38.0 ± 11.5) % (low mean-TMT group) versus (88.3 ± 3.2) % (high mean-TMT group), and OS rates were (57.2 ± 8.7) % versus (96.5 ± 1.7) %, respectively. The multivariate Cox regression revealed significantly better PFS (hazard ratio (HR) = 0.165; 95% confidence interval (CI): 0.064-0.427; P < 0.001) and OS (HR = 0.064; 95% CI: 0.020-0.207; P < 0.001) in patients above versus below this cutoff. These findings were validated in test cohort and two independent validation cohorts.</p><p><strong>Conclusion: </strong>MRI-measured TMT is a potential prognostic indicator for MB patients aged 3-12 years, and may help guide risk stratification and treatment planning. To validate its clinical applicability, large-sample prospective researches remain essential.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"1235-1246"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic radiosurgery for intracranial and spinal adenoid cystic carcinoma: systematic review and illustrative case presentation.","authors":"Juan J Cardona, David J Park, Mohamed F Al Gharyani, Jen-Yeu Wang, Yusuke S Hori, Fred C Lam, Deya Abu-Reesh, Louisa Ustrzynski, Sara C Emrich, Armine Tayag, Gordon Li, Melanie Hayden Gephart, Steven D Chang","doi":"10.1007/s11060-025-05175-x","DOIUrl":"10.1007/s11060-025-05175-x","url":null,"abstract":"<p><strong>Purpose: </strong>Adenoid cystic carcinoma (ACC) is a rare, aggressive malignancy with a predilection for perineural spread and distant metastases. Given the limited but emerging evidence on the role of stereotactic radiosurgery (SRS) in managing intracranial and spinal ACC, a systematic review was deemed necessary to synthesize relevant parameters related to clinical features and management of ACC patients, SRS treatment characteristics, and clinical outcomes across published studies.</p><p><strong>Methods: </strong>This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive search of the PubMed, Scopus, and Embase databases was performed to identify studies evaluating patients with histologically confirmed diagnoses of intracranial and/or spinal ACC who were treated with SRS. Additionally, a unique illustrative case was presented.</p><p><strong>Results: </strong>A total of 129 patients and 211 lesions with ACC were identified from 16 studies published between 1992 and 2025. Patient ages ranged from 10 to 85 years. Lesions were mostly in the intracranial space (n = 194; 91.9%), followed by the spinal column (n = 17; 8.1%). Standalone SRS was administered as primary treatment in 108 lesions (57.1%). Six of eight studies documented a median prescription dose ≥ 15 Gy, while the mean calculated dose among case reports/series with individualized data was 20.8 Gy (SD = 10.4 Gy). Two of four studies recorded a median maximum tumor dose ≥ 30 Gy. Most treatment plans were delivered in a single fraction. Local tumor control (LTC) was achieved in 210/211 lesions (99.5%) over time, although 32/201 lesions eventually experienced local failure (15.9%). LTC duration ranged from 1 to 326 months, and overall survival ranged from 0 to 354 months. A 43-year-old male with concurrent intracranial and spinal ACC treated with CyberKnife SRS is presented.</p><p><strong>Conclusions: </strong>SRS offers favorable LTC for intracranial and spinal ACC, supporting its role as a precise, advanced radiation modality in this challenging context.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"493-505"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical outcomes in octogenarian meningioma patients: a multicenter retrospective analysis of frailty and radiological predictors : Frailty in octogenarians undergoing meningioma resection.","authors":"Pedro David Delgado-López, Antonio Montalvo-Afonso, Roberto García-Leal, Sergio Martín-García, Alfonso Lagares, Ana María Castaño León, Miguel Gelabert-González, Eduardo Arán-Echabe, Carlos A Rodríguez-Arias, Salim Khayat, José F Alén, Amelia Álvarez-Sala, Rosario Sarabia, Olga Esteban Sinovas, Luis Torres Carretero, Angela Dayana Tapia Moscoso, Victor Rodríguez-Domínguez, Alberto Isla Guerrero, Javier Robla Costales, David Santamarta Gómez, Vicente Martín-Velasco, Javier Martín Alonso, Ane Barreras García, Rubén Diana Martín, Eva María Corrales-García","doi":"10.1007/s11060-025-05174-y","DOIUrl":"10.1007/s11060-025-05174-y","url":null,"abstract":"<p><strong>Background: </strong>The rising life expectancy has led to an increased incidence of meningiomas among the elderly. In octogenarians, surgical decision-making remains particularly challenging due to frailty, comorbidities, and the risk of postoperative decline. This study investigates whether preoperative frailty indices and radiological features predict surgical outcomes in this high-risk population.</p><p><strong>Methods: </strong>A multicenter retrospective cohort study was conducted across ten Spanish tertiary care centers, including 189 patients aged ≥ 80 years who underwent intracranial meningioma resection between 2010 and 2023. Preoperative variables included the 5-item Frailty Index (5-FI), Charlson Comorbidity Index (CCI), American Society of Anesthesiologists (ASA) classification, and tumor-specific imaging characteristics (tumor diameter, peritumoral edema, and venous sinus involvement). The primary endpoint was the occurrence of Unfavorable Outcome (any postoperative neurological deficit, 30-day mortality, or major complication). Secondary endpoints included variation of KPS score at 1 year, discharge disposition, and 1-year mortality. Both univariate and multivariate logistic regression models were applied.</p><p><strong>Results: </strong>Mean patient age was 83.0 ± 2.6 years, with 58.2% females. In univariate analysis, preoperative KPS < 70, higher WHO grade, and larger tumor diameter were associated with an unfavorable outcome. However, multivariate analysis identified only preoperative KPS < 70 as an independent predictor of worse outcome (OR 3.10, 95% CI 1.44-6.68, p = 0.004). At 12 months, functional status declined significantly (mean KPS from 73.5 to 63.5; p < 0.001), although 27.1% of patients remained functionally independent. New neurological deficits occurred in 23.8%, postoperative complications in 42.8%, and 30-day mortality was 4.2%. One-year mortality reached 15.8%. Predictors of 12-month KPS < 70 included higher age, preoperative KPS < 70, higher 5-FI, higher ASA grade, higher WHO grade, and the presence of major postoperative complications or new neurological deficits. In multivariate analysis, preoperative KPS < 70 (OR 14.45, 95% CI 5.64-37.03, p < 0.001) and the occurrence of new neurological deficits (OR 4.79, 95% CI 1.59-14.38, p = 0.005) were independent predictors of 12-month KPS < 70.</p><p><strong>Conclusions: </strong>In octogenarians undergoing meningioma surgery, frailty indices-especially low preoperative KPS-and tumor-related characteristics are stronger predictors of surgical outcomes than age alone. Incorporating individualized assessments of physiological reserve and tumor burden may improve surgical planning and preoperative counseling in this growing patient population.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"775-787"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct size and spatial distribution patterns of ALK-inhibitor-naïve versus ALK-inhibitor exposed ALK-positive NSCLC brain metastases.","authors":"Tia Cheunkarndee, Zsombor Ritter, Max Saint-Germain, Paola Ghanem, Kristen A Marrone, Joseph C Murray, Josephine L Feliciano, Christine L Hann, Jordina Rincon Torroella, Solmaz Sahebjam, Susan C Scott, David S Ettinger, Valsamo Anagnostou, Patrick M Forde, Julie R Brahmer, Benjamin P Levy, Vincent K Lam, David O Kamson","doi":"10.1007/s11060-025-05148-0","DOIUrl":"10.1007/s11060-025-05148-0","url":null,"abstract":"<p><strong>Background and purpose: </strong>Non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase rearrangement (ALK+) has a high affinity to form brain metastases (BMs). The cumulative incidence of BMs in ALK + lung cancer is over 50%, despite highly effective ALK tyrosine kinase inhibitors (TKIs) with CNS activity. Pharmacokinetic (PK) data from other CNS-active lung cancer TKIs have raised the possibility of a PK-driven effect on BMs formation and response. This study aims to compare the size and distribution of ALK + NSCLC BMs at diagnosis in a TKI-naïve and TKI-exposed cohort.</p><p><strong>Methods: </strong>We retrospectively reviewed brain MRIs from the date of initial BMs detection for patients diagnosed with ALK + NSCLC at Johns Hopkins between 2007 and 2022. Demographic and clinical information were collected by chart review. Each tumor was marked in a standard space brain model in the corresponding anatomic location represented by a sphere of corresponding diameter. The data for patients who were TKI-naïve, had current or prior treatment with crizotinib, or had current or prior treatment with second-generation TKIs at the time of BMs diagnosis were then analyzed separately to compare the size and localization of BMs between the groups.</p><p><strong>Results: </strong>405 BMs were identified in 48 patients, of which 30 patients TKI-naïve, 11 were crizotinib-treated, and 7 were second-generation TKI-treated. TKI-naïve BMs were significantly larger in diameter than both crizotinib-treated and second-generation TKI-treated BMs (mean diameter 8.78 ± 6.0 mm vs. 6.0 ± 7.2 mm, p < 0.001, and 5.6 ± 3.2 mm, p = 0.003, respectively). Patients in the crizotinib-treated group also had significantly more BMs exclusively in the white matter compared to the other two groups (OR = 1.9 [CI 95%: 1.17-2.99], p = 0.008 and 3.3 [CI 95% 1.52-7.25], p = 0.002, respectively).</p><p><strong>Conclusion: </strong>Our data highlight differences in size and distribution among TKI-naïve, crizotinib-treated, and second-generation TKI-treated BMs in ALK + NSCLC. These findings suggest that suboptimal drug CNS distribution in the white matter may underlie brain progression of ALK + NSCLC despite TKI therapy and raise the possibility of a spatially-mediated resistance mechanism.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"561-569"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the therapeutic effect on tumor cells through wireless optoelectronic stimulation.","authors":"E Iusupovskaia, N Isaev, A Antonian, A K Boromangnaeva, E Kuzmin, G Piavchenko, A Konovalov, G Pavlova, N Samoylenkova, P Timashev, D Telyshev, I Ulasov, Aleksandr Markov","doi":"10.1007/s11060-025-05171-1","DOIUrl":"10.1007/s11060-025-05171-1","url":null,"abstract":"<p><strong>Purpose: </strong>Drug resistance is a major challenge in the treatment of tumor diseases, especially in glioblastoma (GBM), where temozolomide (TMZ) plays a critical role. However, the development of resistance to TMZ occurs rapidly in more than half of the patients who initially respond to the drug. This highlights the need for novel approaches to overcome drug resistance and improve therapeutic outcomes in GBM treatment.</p><p><strong>Methods: </strong>In our study, we combine TMZ treatment with wireless optoelectronics using advanced multilayered organic semiconductor (MOS) devices. These devices consist of a 200 nm thick stack of metal and p-n semiconducting organic nanocrystals. When illuminated in physiological solutions, these MOS devices charge up and convert light pulses into localized displacement currents, which are strong enough to electrically stimulate tumor cells at safe light intensities. Importantly, the freestanding MOS devices require no external wiring or bias and remain stable under physiological conditions. The semiconductor layers are created from common, non-toxic pigments using simple, scalable deposition methods.</p><p><strong>Results: </strong>Our results demonstrate that this combination of TMZ and optoelectronic stimulation significantly enhances apoptosis in tumor cells, thereby improving the effectiveness of TMZ in treating glioblastoma.</p><p><strong>Conclusion: </strong>his research suggests that the integration of wireless optoelectronic stimulation with TMZ treatment offers a promising strategy to overcome drug resistance in GBM. The use of MOS devices enhances the therapeutic effect of TMZ and could lead to better treatment outcomes for patients with glioblastoma.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"741-752"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CLOCK promotes proliferation of glioblastoma cells through acetylating PRPS1/2.","authors":"Juanjuan Liu, Zhaoyuan Meng, Runze Wang, Gaoxiang Zhao, Qingxia Ma, Hongfei Jiang, Leina Ma, Xiangyan Zhang, Zhimin Lu, Jing Fang","doi":"10.1007/s11060-025-05163-1","DOIUrl":"10.1007/s11060-025-05163-1","url":null,"abstract":"<p><strong>Purpose: </strong>The oncogenic impairment of the circadian clock plays an important role in tumorigenesis. However, it remains unclear whether the activation of epidermal growth factor (EGF) receptor (EGFR), which plays a critical role in glioblastoma (GBM) development, regulates the circadian clock and thereby tumorigenesis.</p><p><strong>Methods: </strong>This study employed molecular techniques including DNA mutagenesis, qPCR, immunoprecipitation, immunofluorescence, and functional assays. CLOCK and PRPS1/2 mutants were generated by site-directed mutagenesis, and gene silencing was performed using shRNA. Gene expression levels were quantified by qPCR, whereas CLOCK localization was analyzed through immunofluorescence and subcellular fractionation. The effects of EGF on GBM cell proliferation and migration were assessed via functional assays. In GBM specimens, the expression of PRPS1/2, CLOCK pS106, and PRPS1/2 K29ac was evaluated by IHC and correlated with tumor aggressiveness and patient survival.</p><p><strong>Results: </strong>EGF induced CK2-mediated CLOCK S106 phosphorylation, disrupting CLOCK-BMAL1 heterodimerization and suppressing circadian gene expression. Phosphorylated CLOCK bound Exportin1, leading to its nuclear export. Cytosolic CLOCK acetylated PRPS1/2 at K29, preventing HSC70-mediated degradation and enhancing GBM cell proliferation and migration. In human GBM samples, CLOCK pS106, PRPS1/2 K29ac, and PRPS1/2 levels correlated positively with advanced tumor stage and poor survival.</p><p><strong>Conclusion: </strong>EGF-activated CK2α phosphorylated CLOCK at S106, disrupting circadian rhythms and inducing CLOCK-dependent PRPS1/2 K29 acetylation to drive GBM progression. Clinically, CLOCK pS106, PRPS1/2 K29ac, and PRPS1/2 overexpression correlated with aggressive tumors and poorer prognosis, identifying an EGFR-CLOCK-PRPS1/2 oncogenic axis.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"657-671"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden of brain and central nervous system cancer in 185 countries, and projections up to 2050: a population-based systematic analysis of GLOBOCAN 2022.","authors":"Seokjun Kim, Yejun Son, Jiyeon Oh, Soeun Kim, Wonwoo Jang, Sooji Lee, Lee Smith, Damiano Pizzol, Jinseok Lee, Hayeon Lee, Christa J Nehs, Matthew A Nehs, Junyang Jung, Jiseung Kang, Dong Keon Yon","doi":"10.1007/s11060-025-05164-0","DOIUrl":"10.1007/s11060-025-05164-0","url":null,"abstract":"<p><strong>Background: </strong>Brain and central nervous system (CNS) cancers are associated with high mortality and morbidity. Here, we aimed to systematically evaluate and compare brain and CNS cancer between pediatric and adult populations.</p><p><strong>Methods: </strong>This study utilized the GLOBOCAN 2022 database to analyze incidence and mortality estimates for brain and CNS cancers across 185 countries and territories in 2022. Joinpoint regression was employed to estimate the average annual percent change in age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASMR).</p><p><strong>Results: </strong>In 2022, the global estimated ASIR of brain and CNS cancers was 3.5 per 100,000 people, with 321,624 new cases. An estimated 248,403 deaths were attributed to brain and CNS cancer, with an ASMR of 2.6 per 100,000 people. In 2022, pediatric brain and CNS cancers in individuals aged 0-14 years ranked second globally for both incidence and mortality across various cancer subtypes, while for individuals aged ≥ 15 years, they ranked 19th and 12th, respectively. Globally, the mortality-to-incidence ratios of brain and CNS cancer were 47.7% in pediatrics aged 0-14 years and 77.8% in individuals aged ≥ 15 years, respectively. By 2050, if current trends persist, brain and CNS cancer among individuals aged 0-14 years is projected to decrease by 9.2% globally, but this trend is limited to countries with higher Human Development Index (HDI). Among individuals aged ≥ 15 years, if incidence rates remain constant, global estimated cases of brain and CNS cancer are projected to increase by 32.9% by 2050 and all HDI subgroups are predicted to experience an upward trend in incidence, with the magnitude of increase being more significant in lower HDI up to 2050.</p><p><strong>Conclusion: </strong>This study identified substantial geographical and socioeconomic inequalities in the brain and CNS cancers globally, with potential underreporting concerns in pediatric cases and increasing burdens predicted up to 2050, particularly in lower HDI countries.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"673-685"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined effects of escitalopram and vitamin E on phoenixin-20 secretion and neuroregulatory mechanisms in glioblastoma cells: a neuro-nutritional perspective.","authors":"İrem Aydemir, Gizem Tutkun, Esra Tanyel Akcit, Orhan Kocak, Altinay Altinkaynak, Kubra Yildirim, Ece Simsek, Ahmet Yilmaz Coban","doi":"10.1007/s11060-025-05176-w","DOIUrl":"10.1007/s11060-025-05176-w","url":null,"abstract":"<p><strong>Objective: </strong>Glioblastoma multiforme (GBM) is one of the most aggressive brain tumors, characterized by limited treatment options due to the blood-brain barrier and drug resistance. Escitalopram (Citoles), a selective serotonin reuptake inhibitor (SSRI), has recently attracted attention for its potential anti-tumor properties. This study aimed to evaluate the effects of Citoles and vitamin E on GBM cell viability, Phoenixin-20 (PNX-20) secretion, and their molecular interaction with the GPR-173 receptor.</p><p><strong>Methods: </strong>U87-MG glioblastoma cells were treated with various concentrations of Citoles and vitamin E, both individually and in combination. Cell viability was assessed using Trypan Blue exclusion and MTT assays. PNX-20 secretion was quantified via ELISA, and the binding potential of the compounds with GPR-173 was examined through in silico molecular docking analysis.</p><p><strong>Results: </strong>The combination treatment significantly reduced cell viability. ELISA results indicated that PNX-20 secretion increased markedly at 48 and 72 h post-treatment. Molecular docking analysis revealed that both compounds exhibited high binding affinity to the GPR-173 receptor, supporting their potential mechanisms of action.</p><p><strong>Conclusion: </strong>The combined use of Citoles and vitamin E demonstrated antiproliferative effects on GBM cells and significantly enhanced PNX-20 secretion, suggesting a meaningful neuropeptidergic response. These findings highlight the therapeutic potential of SSRIs in bridging neuroregulation and cancer biology.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"789-799"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic profiling reveals dynamic regulation of vesicle trafficking across glioma grades.","authors":"Tomasz Pienkowski, Patrycja Mojsak, Tomasz Kowalczyk, Dominik Cysewski, Mikolaj Krupa, Robert Rutkowski, Zenon Mariak, Adrian Godlewski, Joanna Reszec, Marcin Moniuszko, Adam Kretowski, Tomasz Lyson, Michal Ciborowski","doi":"10.1007/s11060-025-05151-5","DOIUrl":"10.1007/s11060-025-05151-5","url":null,"abstract":"<p><strong>Purpose: </strong>Gliomas are highly heterogeneous central nervous system tumors that evolve through progressive molecular reprogramming. While cell proliferation and adhesion mechanisms are well-characterized, the contribution of vesicle trafficking to glioma progression remains underexplored. This study aimed to characterize proteomic changes across glioma grades.</p><p><strong>Methods: </strong>We performed untargeted, quantitative proteomic profiling of glioma tissues across WHO grades I-IV using a combination of Tandem Mass Tag (TMT)-11plex labeling and high-resolution liquid chromatography-mass spectrometry (LC-MS). Tissue samples were processed using filter-aided sample preparation (FASP) and analyzed using a µPAC reverse-phase HPLC system coupled to a high-resolution mass spectrometer. Protein identification and quantification were conducted through database searching and validated against stringent quality control criteria.</p><p><strong>Results: </strong>We identified over 4,400 proteins across samples, revealing dynamic, grade-specific shifts in vesicle trafficking. Grade II gliomas showed upregulation of exocytic proteins (e.g., synaptotagmin, syntaxin, clathrin) and suppression of dynamin, suggesting enhanced vesicular secretion. Grade III tumors exhibited the opposite trend-marked downregulation of exocytic components with concurrent activation of clathrin-mediated endocytosis. Grade IV gliomas displayed a hybrid profile, with partial reactivation of exocytic machinery alongside sustained endocytic activity, indicative of vesicular plasticity.</p><p><strong>Conclusion: </strong>This study highlights the synaptic vesicle cycle as a progressively remodeled pathway in glioma biology. Our findings suggest that vesicle trafficking is a critical, underrecognized feature of glioma pathogenesis and may represent a novel axis for therapeutic exploration.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"585-598"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic radiosurgery for recurrent high-grade gliomas: a systematic review.","authors":"Trent Kite, Bryce Bossinger, Vineetha Yadlapalli, Stephen Jaffee, John Herbst, Stephen Karlovits, Rodney E Wegner, Matthew J Shepard","doi":"10.1007/s11060-025-05156-0","DOIUrl":"10.1007/s11060-025-05156-0","url":null,"abstract":"<p><strong>Purpose: </strong>Management of recurrent high-grade glioma (rHGG) is challenging. Contemporary therapeutic approaches include systemic chemotherapy, resection, conventional radiation, and stereotactic radiosurgery (SRS). Stereotactic radiosurgery is increasingly utilized given its low toxicity rates and relative efficacy. As the pace of research on this topic is rapidly evolving, a comprehensive review of the existing literature is necessary.</p><p><strong>Methods: </strong>A systematic review in accordance with the preferred reporting in systematic review and meta-analysis guidelines (PRISMA) was conducted. PubMed and Science Direct databases were queried for articles which reported a primary analysis on a cohort of patients with recurrent gliomas (WHO grade III and IV) treated with SRS. Articles meeting the inclusion criteria and satisfying the quality threshold were included in the final review.</p><p><strong>Results: </strong>In total 22 articles representing 1,191 patients satisfied the inclusion criteria and quality threshold. The articles spanned a time frame from 1999 to March 2025. Tumor subtypes were distributed as 245 (20.6%) grade III and 946 (79.4%) grade IV. Linear accelerator (LINAC) based SRS was the most frequently utilized SRS platform treating a median tumor volume of 9.9cm³ (range: 1.21-44.0) with a median prescription dose of 16.5 Gy. At one-year, the pooled actuarial survival was 53%. At the time of last radiographic follow up, the pooled local progression and distant progression were 58% and 35% respectively. Grade ≥ 3 toxicity ranged from 0 to 14%.</p><p><strong>Conclusions: </strong>For patients undergoing SRS for rHGG, overall survival times are consistent with alternative salvage therapies (chemotherapy, resection, and conventional radiotherapy) with relatively low treatment-related toxicity. Certain factors such as age, Karnofsky performance status (KPS), WHO grade, and interval between primary tumor treatment and reccurence/salvage SRS may be important in predicting treatment response.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"481-491"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}